CY1111316T1 - Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης - Google Patents

Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης

Info

Publication number
CY1111316T1
CY1111316T1 CY20111100040T CY111100040T CY1111316T1 CY 1111316 T1 CY1111316 T1 CY 1111316T1 CY 20111100040 T CY20111100040 T CY 20111100040T CY 111100040 T CY111100040 T CY 111100040T CY 1111316 T1 CY1111316 T1 CY 1111316T1
Authority
CY
Cyprus
Prior art keywords
rheumatoid arthritis
thiazolo
amino
substituted
pyrimidine
Prior art date
Application number
CY20111100040T
Other languages
Greek (el)
English (en)
Inventor
Gunnar Nordvall
Colin Ray
Tobias Rein
Daniel D Sohn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1111316T1 publication Critical patent/CY1111316T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY20111100040T 2005-04-06 2011-01-13 Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης CY1111316T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0500767 2005-04-06
EP06717078A EP1869056B1 (en) 2005-04-06 2006-04-03 Novel 5-substituted 7-amino-ý1,3¨thiazoloý4,5-d¨pyrimidine derivatives

Publications (1)

Publication Number Publication Date
CY1111316T1 true CY1111316T1 (el) 2015-08-05

Family

ID=37073739

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100040T CY1111316T1 (el) 2005-04-06 2011-01-13 Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης

Country Status (30)

Country Link
US (2) US7947693B2 (enExample)
EP (1) EP1869056B1 (enExample)
JP (1) JP5165553B2 (enExample)
KR (1) KR101335055B1 (enExample)
CN (1) CN101193897B (enExample)
AR (1) AR055890A1 (enExample)
AT (1) ATE487727T1 (enExample)
AU (1) AU2006231836B2 (enExample)
BR (1) BRPI0609738A2 (enExample)
CA (1) CA2604017C (enExample)
CY (1) CY1111316T1 (enExample)
DE (1) DE602006018124D1 (enExample)
DK (1) DK1869056T3 (enExample)
ES (1) ES2354450T3 (enExample)
HR (1) HRP20110047T1 (enExample)
IL (1) IL185912A0 (enExample)
MX (1) MX2007012060A (enExample)
NO (1) NO20075603L (enExample)
NZ (1) NZ561460A (enExample)
PL (1) PL1869056T3 (enExample)
PT (1) PT1869056E (enExample)
RS (1) RS51581B (enExample)
RU (1) RU2419623C2 (enExample)
SA (1) SA06270072B1 (enExample)
SI (1) SI1869056T1 (enExample)
TW (1) TW200714605A (enExample)
UA (1) UA90707C2 (enExample)
UY (1) UY29454A1 (enExample)
WO (1) WO2006107258A1 (enExample)
ZA (1) ZA200708187B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
RU2437889C2 (ru) * 2006-09-29 2011-12-27 Астразенека Аб НОВЫЕ 5,7-ДИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ [1,3]ТИАЗОЛО[4,5-d]ПИРИМИДИН-2-(3Н)-АМИНА И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
EP2262778B8 (en) 2008-03-07 2020-01-01 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
KR101581829B1 (ko) 2008-03-07 2015-12-31 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1 및 ｃｘ3ｃｒ1의 발현을 기초로 한 질환들의 치료에서 이의 용도
KR101581828B1 (ko) 2008-03-07 2015-12-31 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도
CA2762680C (en) 2009-05-21 2018-04-17 Chlorion Pharma, Inc. Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US8476301B2 (en) 2011-09-13 2013-07-02 Eisai R&D Management Co., Ltd. Pyrrolidin-3-ylacetic acid derivative
JO3082B1 (ar) 2011-09-13 2017-03-15 Eisai R&D Man Co Ltd مشتق بيروليدين-3- يل حمض خليك
CA2900926A1 (en) 2013-03-12 2014-09-18 Eisai R&D Management Co., Ltd. Salt of pyrrolidin-3-yl acetic acid derivative and crystals thereof
WO2015048281A1 (en) * 2013-09-27 2015-04-02 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2016200939A1 (en) * 2015-06-08 2016-12-15 The Johns Hopkins University Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1)
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
GB201807898D0 (en) 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
GB202006849D0 (en) 2020-05-08 2020-06-24 Kancera Ab New use
AU2023362450A1 (en) 2022-10-19 2025-05-29 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3 cr1
WO2025219939A1 (en) 2024-04-17 2025-10-23 Astrazeneca Ab Salts and polymorphs of cx3cr1 modulators
WO2025219947A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Thio-substituted 1,3,5-triazine cx3cr1 modulators
WO2025219950A1 (en) 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE543978A (enExample) 1955-01-03
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
EP0891978B1 (en) * 1997-07-18 2002-03-20 F. Hoffmann-La Roche Ag 5H-Thiazolo (3,2-a) pyrimidine derivatives
CA2326884A1 (en) 1998-04-03 1999-10-14 Dupont Pharmaceuticals Company Thiazolo¬4,5-d|pyrimidines and pyridines as corticotropin releasing factor (crf) antagonists
JP4307723B2 (ja) 1998-05-01 2009-08-05 イーライ リリー アンド カンパニー Ｎ１−修飾グリコペプチド
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
JP2003522191A (ja) * 2000-02-11 2003-07-22 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性のモジュレーターとしてのピリミジン化合物およびそれらの使用
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
SE0004110L (sv) 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
WO2004057959A2 (en) * 2002-12-20 2004-07-15 Generipharm, Inc. Intracutaneous injection
WO2005033115A1 (en) 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos

Also Published As

Publication number Publication date
SI1869056T1 (sl) 2011-02-28
US20080214578A1 (en) 2008-09-04
AR055890A1 (es) 2007-09-12
NZ561460A (en) 2010-12-24
HK1118556A1 (en) 2009-02-13
HRP20110047T1 (hr) 2011-03-31
PT1869056E (pt) 2011-01-13
DE602006018124D1 (de) 2010-12-23
JP5165553B2 (ja) 2013-03-21
ATE487727T1 (de) 2010-11-15
CN101193897A (zh) 2008-06-04
RU2007140551A (ru) 2009-05-20
KR101335055B1 (ko) 2013-12-02
ZA200708187B (en) 2008-11-26
EP1869056A4 (en) 2010-02-17
EP1869056A1 (en) 2007-12-26
JP2008535835A (ja) 2008-09-04
ES2354450T3 (es) 2011-03-15
KR20080004483A (ko) 2008-01-09
AU2006231836B2 (en) 2010-07-15
CA2604017A1 (en) 2006-10-12
TW200714605A (en) 2007-04-16
NO20075603L (no) 2008-01-04
US20110092519A1 (en) 2011-04-21
UY29454A1 (es) 2006-11-30
CA2604017C (en) 2012-03-06
MX2007012060A (es) 2007-12-13
RU2419623C2 (ru) 2011-05-27
US9440992B2 (en) 2016-09-13
US7947693B2 (en) 2011-05-24
CN101193897B (zh) 2010-12-01
BRPI0609738A2 (pt) 2011-10-18
RS51581B (sr) 2011-08-31
SA06270072B1 (ar) 2009-02-07
PL1869056T3 (pl) 2011-04-29
EP1869056B1 (en) 2010-11-10
UA90707C2 (en) 2010-05-25
IL185912A0 (en) 2008-01-06
WO2006107258A1 (en) 2006-10-12
DK1869056T3 (da) 2011-02-07
AU2006231836A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
TW200714605A (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
WO2007002293A3 (en) Azaindazole compounds and methods of use
CY1110952T1 (el) Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3
CY1107856T1 (el) Παραγωγα ιμιδαζολιου ως ανταγωνιστες υποδοχεα γλουταμινικου
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
CY1107401T1 (el) Παραγωγα βενζοθειαζολιου πα την θεραπευτικη αντιμετωπιση της νοσου alzheimer και της νοσου parkinson
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
CY1111032T1 (el) Παραγωγα τετραλινης και ινδανιου και οι χρησεις αυτων
NO20075610L (no) Nye 5,7-disubstituerte [1,3]tiazol[4,5-d]pyrlmldin-2(3H)-onderivater
CY1114708T1 (el) Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης
CY1107244T1 (el) Μιμητικα γλυκοκορτικοειδων, μεθοδοι παρασκευης τους, φαρμακευτικες συνθεσεις και χρησεις τους
EP2155203A4 (en) Azaindazole compounds and methods of use
CY1108752T1 (el) Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα
CY1111921T1 (el) 7-[2-[4-(6-ΦΘΟΡΟ-3-ΜΕΘΥΛ-1,2-ΒΕΝΖΙΣΟΞΑΖΟΛ-5-ΥΛ)-1-ΠΙΠΕΡΑΖΙΝΥΛ]ΑΙΘΥΛ]-2-(1-ΠΡΟΠΥΝΥΛ)-7Η-ΠΥΡΑΖΟΛΟ-[4,3-e]-[1,2,4]-ΤΡΙΑΖΟΛΟ[1,5-c]ΠΥΡΙΜΙΔΙΝ-5-ΑΜΙΝΗ
EA201070841A1 (ru) НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
UY31734A (es) Nuevos derivados 258 5, 7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
WO2008039139A8 (en) Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy
MX2009003005A (es) Nuevos derivados 5,7-disustituidos de [1,3] tiazolo [4,5-d]pirimidin-2(3h)-ona y su uso en terapia.
ATE482955T1 (de) Azabicyclooctan-3-onderivate und deren verwendung
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
TW200700067A (en) Substituted aryl 1,4-pyrazine derivatives